Extracellular nicotinamide phosphoribosyltransferase (NAMPT) promotes M2 macrophage polarization in chronic lymphocytic leukemia

Blood

Volumn 125, Issue 1, 2015, Pages 111-123

  Audrito, Valentina ^a,b   Serra, Sara ^a,b   Brusa, Davide ^a,b   Mazzola, Francesca ^c   Arruga, Francesca ^a,b   Vaisitti, Tiziana ^a,b   Coscia, Marta ^d   Maffei, Rossana ^e   Rossi, Davide ^f   Wang, Tao ^g   Inghirami, Giorgio ^d,h,i   Rizzi, Menico ^f   Gaidano, Gianluca ^f   Garcia, Joe G N ^j   Wolberger, Cynthia ^g   Raffaelli, Nadia ^c   Deaglio, Silvia ^a,b  

^a UNIVERSITY OF TURIN   (Italy)

^b Human Genetics Foundation   (Italy)

^c UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^d UNIVERSITY OF TURIN   (Italy)

^e UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^f UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^g JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h WEILL CORNELL MEDICAL COLLEGE   (United States)

ⁱ NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j UNIVERSITY OF ARIZONA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE RECEPTOR; CC CHEMOKINE LIGAND 18; CD163 ANTIGEN; CD206 ANTIGEN; CHEMOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOLEAMINE 2,3 DIOXYGENASE; INTERFERON REGULATORY FACTOR 4; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE DERIVED CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PROTEIN; STAT3 PROTEIN; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG; CELL SURFACE RECEPTOR; DIFFERENTIATION ANTIGEN; LECTIN; LEUKOCYTE ANTIGEN; MANNOSE BINDING LECTIN; MANNOSE RECEPTOR; STAT3 PROTEIN, HUMAN;

ARTICLE; CELL DIFFERENTIATION; CELL LEVEL; CELL STRUCTURE; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; LYMPHOCYTE; M2 MACROPHAGE; MACROPHAGE; MONOCYTE; POLARIZATION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; UPREGULATION; AGED; B LYMPHOCYTE; BLOOD DONOR; CELL PROLIFERATION; CONFOCAL MICROSCOPY; CYTOLOGY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYMOLOGY; FEMALE; MALE; METABOLISM; MUTATION; PHAGOCYTOSIS;

AGED; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; B-LYMPHOCYTES; BLOOD DONORS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INTERLEUKIN-10; LECTINS, C-TYPE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MACROPHAGES; MALE; MANNOSE-BINDING LECTINS; MICROSCOPY, CONFOCAL; MONOCYTES; MUTATION; NF-KAPPA B; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PHAGOCYTOSIS; RECEPTORS, CELL SURFACE; STAT3 TRANSCRIPTION FACTOR;

EID: 84920581665     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-07-589069     Document Type: Article

References (78)

1. Sica A, Allavena P, Mantovani A. Cancer related inflammation: the macrophage connection. Cancer Lett. 2008;267(2):204-215.
2. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010;141(1):39-51.
3. Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol. 2010;11(10): 889-896.
4. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860-867.
5. Burger JA, Ghia P, Rosenwald A, Caligaris-Cappio F. The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood. 2009;114(16):3367-3375.
6. Zenz T, Mertens D, Küppers R, Döhner H, Stilgenbauer S. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer. 2010;10(1):37-50.
7. Audrito V, Vaisitti T, Serra S, et al. Targeting the microenvironment in chronic lymphocytic leukemia offers novel therapeutic options. Cancer Lett. 2013;328(1):27-35.
8. Ponzoni M, Doglioni C, Caligaris-Cappio F. Chronic lymphocytic leukemia: the pathologist's view of lymph node microenvironment. Semin Diagn Pathol. 2011;28(2):161-166.
9. Fecteau JF, Kipps TJ. Structure and function of the hematopoietic cancer niche: focus on chronic lymphocytic leukemia. Front Biosci (Schol Ed). 2012;4:61-73.
10. Ferretti E, Bertolotto M, Deaglio S, et al. A novel role of the CX3CR1/CX3CL1 system in the crosstalk between chronic lymphocytic leukemia cells and tumor microenvironment. Leukemia. 2011; 25(8):1268-1277.
11. Ysebaert L, Fournié JJ. Genomic and phenotypic characterization of nurse-like cells that promote drug resistance in chronic lymphocytic leukemia. Leuk Lymphoma. 2011;52(7):1404-1406.
12. Filip AA, Ciseł B, Koczkodaj D, Wasik-Szczepanek E, Piersiak T, Dmoszyńska A. Circulating microenvironment of CLL: are nurse-like cells related to tumor-associated macrophages? Blood Cells Mol Dis. 2013;50(4): 263-270.
13. Maffei R, Bulgarelli J, Fiorcari S, et al. The monocytic population in chronic lymphocytic leukemia shows altered composition and deregulation of genes involved in phagocytosis and inflammation. Haematologica. 2013;98(7): 1115-1123.
14. Burger JA, Tsukada N, Burger M, Zvaifler NJ, Dell'Aquila M, Kipps TJ. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood. 2000;96(8):2655-2663.
15. Burger JA, Kipps TJ. Chemokine receptors and stromal cells in the homing and homeostasis of chronic lymphocytic leukemia B cells. Leuk Lymphoma. 2002;43(3):461-466.
16. Tsukada N, Burger JA, Zvaifler NJ, Kipps TJ. Distinctive features of "nurselike" cells that differentiate in the context of chronic lymphocytic leukemia. Blood. 2002;99(3):1030-1037.
17. Samal B, Sun Y, Stearns G, Xie C, Suggs S, McNiece I. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol. 1994; 14(2):1431-1437.
18. Chang YH, Chang DM, Lin KC, Shin SJ, Lee YJ. Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: a meta-analysis and systemic review. Diabetes Metab Res Rev. 2011; 27(6):515-527.
19. Martin PR, Shea RJ, Mulks MH. Identification of a plasmid-encoded gene from Haemophilus ducreyi which confers NAD independence. J Bacteriol. 2001;183(4):1168-1174.
20. Rongvaux A, Shea RJ, Mulks MH, et al. Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis. Eur J Immunol. 2002;32(11):3225-3234.
21. Houtkooper RH, Cantó C, Wanders RJ, Auwerx J. The secret life of NAD+: an old metabolite controlling new metabolic signaling pathways. Endocr Rev. 2010;31(2):194-223.
22. Li Y, Zhang Y, Dorweiler B, et al. Extracellular Nampt promotes macrophage survival via a nonenzymatic interleukin-6/STAT3 signaling mechanism. J Biol Chem. 2008;283(50): 34833-34843.
23. Liu P, Li H, Cepeda J, et al. Regulation of inflammatory cytokine expression in pulmonary epithelial cells by pre-B-cell colony-enhancing factor via a nonenzymatic and AP-1-dependent mechanism. J Biol Chem. 2009;284(40): 27344-27351.
24. Sun Z, Lei H, Zhang Z. Pre-B cell colony enhancing factor (PBEF), a cytokine with multiple physiological functions. Cytokine Growth Factor Rev. 2013;24(5):433-442.
25. Zhang LQ, Heruth DP, Ye SQ. Nicotinamide phosphoribosyltransferase in human diseases. J Bioanal Biomed. 2011;3:13-25.
26. Gallí M, Van Gool F, Rongvaux A, Andris F, Leo O. The nicotinamide phosphoribosyltransferase: a molecular link between metabolism, inflammation, and cancer. Cancer Res. 2010; 70(1):8-11.
27. Garten A, Petzold S, Körner A, Imai S, Kiess W. Nampt: linking NAD biology, metabolism and cancer. Trends Endocrinol Metab. 2009;20(3): 130-138.
28. Imai S. Nicotinamide phosphoribosyltransferase (Nampt): a link between NAD biology, metabolism, and diseases. Curr Pharm Des. 2009;15(1):20-28.
29. Jieyu H, Chao T, Mengjun L, et al. Nampt/visfatin/ PBEF: a functionally multi-faceted protein with a pivotal role in malignant tumors. Curr Pharm Des. 2012;18(37):6123-6132.
30. Vaisitti T, Audrito V, Serra S, et al. The enzymatic activities of CD38 enhance CLL growth and trafficking: implications for therapeutic targeting [published online ahead of print July 3, 2014]. Leukemia.
31. Deaglio S, Vaisitti T, Bergui L, et al. CD38 and CD100 lead a network of surface receptors relaying positive signals for B-CLL growth and survival. Blood. 2005;105(8):3042-3050.
32. Hong SB, Huang Y, Moreno-Vinasco L, et al. Essential role of pre-B-cell colony enhancing factor in ventilator-induced lung injury. Am J Respir Crit Care Med. 2008;178(6):605-617.
33. Pillai VB, Sundaresan NR, Kim G, et al. Nampt secreted from cardiomyocytes promotes development of cardiac hypertrophy and adverse ventricular remodeling. Am J Physiol Heart Circ Physiol. 2013;304(3):H415-H426.
34. Zamporlini F, Ruggieri S, Mazzola F, Amici A, Orsomando G, Raffaelli N. Novel assay for simultaneous measurement of pyridine mononucleotides synthesizing activities allows dissection of the NAD(+) biosynthetic machinery in mammalian cells [published online ahead of print October 4, 2014]. FEBS J.
35. Graeff R, Lee HC. A novel cycling assay for nicotinic acid-adenine dinucleotide phosphate with nanomolar sensitivity. Biochem J. 2002; 367(pt 1):163-168.
36. Formentini L, Moroni F, Chiarugi A. Detection and pharmacological modulation of nicotinamide mononucleotide (NMN) in vitro and in vivo. Biochem Pharmacol. 2009;77(10):1612-1620.
37. Deaglio S, Capobianco A, Bergui L, et al. CD38 is a signaling molecule in B-cell chronic lymphocytic leukemia cells. Blood. 2003;102(6):2146-2155.
38. Serra S, Horenstein AL, Vaisitti T, et al. CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death. Blood. 2011;118(23):6141-6152.
39. Tsai YM, Hsu SC, Zhang J, et al. Functional interaction of cockroach allergens and mannose receptor (CD206) in human circulating fibrocytes. PLoS ONE. 2013;8(5):e64105.
40. Arruga F, Gizdic B, Serra S, et al. Functional impact of NOTCH1 mutations in chronic lymphocytic leukemia. Leukemia. 2014;28(5): 1060-1070.
41. Vaisitti T, Aydin S, Rossi D, et al. CD38 increases CXCL12-mediated signals and homing of chronic lymphocytic leukemia cells. Leukemia. 2010; 24(5):958-969.
42. Audrito V, Vaisitti T, Rossi D, et al. Nicotinamide blocks proliferation and induces apoptosis of chronic lymphocytic leukemia cells through activation of the p53/miR-34a/SIRT1 tumor suppressor network. Cancer Res. 2011;71(13): 4473-4483.
43. Giannoni P, Pietra G, Travaini G, et al. Chronic lymphocytic leukemia nurse-like cells express hepatocyte growth factor receptor (c-MET) and indoleamine 2,3-dioxygenase and display features of immunosuppressive type 2 skewed macrophages. Haematologica. 2014;99(6): 1078-1087.
44. Revollo JR, Grimm AA, Imai S. The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. J Biol Chem. 2004;279(49): 50754-50763.
45. Zucchetto A, Benedetti D, Tripodo C, et al. CD38/ CD31, the CCL3 and CCL4 chemokines, and CD49d/vascular cell adhesion molecule-1 are interchained by sequential events sustaining chronic lymphocytic leukemia cell survival. Cancer Res. 2009;69(9):4001-4009.
46. Guarini A, Chiaretti S, Tavolaro S, et al. BCR ligation induced by IgM stimulation results in gene expression and functional changes only in IgV H unmutated chronic lymphocytic leukemia (CLL) cells. Blood. 2008;112(3):782-792.
47. Kenny EF, Quinn SR, Doyle SL, Vink PM, van Eenennaam H, O'Neill LA. Bruton's tyrosine kinase mediates the synergistic signalling between TLR9 and the B cell receptor by regulating calcium and calmodulin. PLoS ONE. 2013;8(8):e74103.
48. Rodríguez-Alba JC, Moreno-García ME, Sandoval-Montes C, Rosales-Garcia VH, Santos-Argumedo L. CD38 induces differentiation of immature transitional 2 B lymphocytes in the spleen. Blood. 2008;111(7):3644-3652.
49. Herman SE, Gordon AL, Hertlein E, et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 2011;117(23):6287-6296.
50. Friebe D, Neef M, Kratzsch J, et al. Leucocytes are a major source of circulating nicotinamide phosphoribosyltransferase (NAMPT)/pre-B cell colony (PBEF)/visfatin linking obesity and inflammation in humans. Diabetologia. 2011; 54(5):1200-1211.
51. Jacques C, Holzenberger M, Mladenovic Z, et al. Proinflammatory actions of visfatin/nicotinamide phosphoribosyltransferase (Nampt) involve regulation of insulin signaling pathway and Nampt enzymatic activity. J Biol Chem. 2012;287(18): 15100-15108.
52. Romacho T, Azcutia V, Vázquez-Bella M, et al. Extracellular PBEF/NAMPT/visfatin activates pro-inflammatory signalling in human vascular smooth muscle cells through nicotinamide phosphoribosyltransferase activity. Diabetologia. 2009;52(11):2455-2463.
53. Hara N, Yamada K, Shibata T, Osago H, Tsuchiya M. Nicotinamide phosphoribosyltransferase/ visfatin does not catalyze nicotinamide mononucleotide formation in blood plasma. PLoS ONE. 2011;6(8):e22781.
54. Cols M, Barra CM, He B, et al. Stromal endothelial cells establish a bidirectional crosstalk with chronic lymphocytic leukemia cells through the TNF-related factors BAFF, APRIL, and CD40L. J Immunol. 2012;188(12):6071-6083.
55. Ferrer G, Bosch R, Hodgson K, et al. B cell activation through CD40 and IL4R ligation modulates the response of chronic lymphocytic leukaemia cells to BAFF and APRIL. Br J Haematol. 2014;164(4):570-578.
56. Yun MR, Seo JM, Park HY. Visfatin contributes to the differentiation of monocytes into macrophages through the differential regulation of inflammatory cytokines in THP-1 cells. Cell Signal. 2014;26(4): 705-715.
57. Skokowa J, Lan D, Thakur BK, et al. NAMPT is essential for the G-CSF-induced myeloid differentiation via a NAD(+)-sirtuin-1-dependent pathway. Nat Med. 2009;15(2):151-158.
58. Moschen AR, Kaser A, Enrich B, et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol. 2007; 178(3):1748-1758.
59. Zucchetto A, Tripodo C, Benedetti D, et al. Monocytes/macrophages but not T lymphocytes are the major targets of the CCL3/CCL4 chemokines produced by CD38(+)CD49d(+) chronic lymphocytic leukaemia cells. Br J Haematol. 2010;150(1):111-113.
60. Ko SY, Ladanyi A, Lengyel E, Naora H. Expression of the homeobox gene HOXA9 in ovarian cancer induces peritoneal macrophages to acquire an M2 tumor-promoting phenotype. Am J Pathol. 2014;184(1):271-281.
61. Martinez FO, Gordon S, Locati M, Mantovani A. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J Immunol. 2006;177(10):7303-7311.
62. Jia L, Clear A, Liu FT, et al. Extracellular HMGB1 promotes differentiation of nurse-like cells in chronic lymphocytic leukemia. Blood. 2014; 123(11):1709-1719.
63. Fiorcari S, Martinelli S, Bulgarelli J, et al. Lenalidomide interferes with tumor-promoting properties of nurse-like cells in chronic lymphocytic leukemia. Haematologica. In press.
64. Moros A, Rodríguez V, Saborit-Villarroya I, et al. Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma. Leukemia. 2014;28(10):2049-2059.
65. Fan Y, Meng S, Wang Y, Cao J, Wang C. Visfatin/ PBEF/Nampt induces EMMPRIN and MMP-9 production in macrophages via the NAMPT-MAPK (p38, ERK1/2)-NF-kB signaling pathway. Int J Mol Med. 2011;27(4):607-615.
66. Brusa D, Serra S, Coscia M, et al. The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia. Haematologica. 2013;98(6): 953-963.
67. Wang T, Zhang X, Bheda P, Revollo JR, Imai S, Wolberger C. Structure of Nampt/PBEF/visfatin, a mammalian NAD+ biosynthetic enzyme. Nat Struct Mol Biol. 2006;13(7):661-662.
68. Chiarugi A, Dölle C, Felici R, Ziegler M. The NAD metabolome-a key determinant of cancer cell biology. Nat Rev Cancer. 2012;12(11):741-752.
69. Liebes LF, Krigel RL, Conklyn M, Nevrla DR, Silber R. Ribonucleotide content of mononuclear cells from normal subjects and patients with chronic lymphocytic leukemia: increased nicotinamide adenine dinucleotide concentration in chronic lymphocytic leukemia lymphocytes. Cancer Res. 1983;43(11):5608-5617.
70. Nahimana A, Attinger A, Aubry D, et al. The NAD biosynthesis inhibitor APO866 has potent antitumor activity against hematologic malignancies. Blood. 2009;113(14):3276-3286.
71. Montecucco F, Cea M, Bauer I, et al. Nicotinamide phosphoribosyltransferase (NAMPT) inhibitors as therapeutics: rationales, controversies, clinical experience. Curr Drug Targets. 2013;14(6):637-643.
72. Gehrke I, Bouchard ED, Beiggi S, et al. On-target effect of FK866, a nicotinamide phosphoribosyl transferase inhibitor, by apoptosis-mediated death in chronic lymphocytic leukemia cells. Clin Cancer Res. 2014;20(18):4861-4872.
73. Schafer ZT, Brugge JS. IL-6 involvement in epithelial cancers. J Clin Invest. 2007;117(12): 3660-3663.
74. Xu H, Lai W, Zhang Y, et al. Tumor-associated macrophage-derived IL-6 and IL-8 enhance invasive activity of LoVo cells induced by PRL-3 in a KCNN4 channel-dependent manner. BMC Cancer. 2014;14(1):330.
75. Uyttenhove C, Pilotte L, Théate I, et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med. 2003;9(10): 1269-1274.
76. Revollo JR, Körner A, Mills KF, et al. Nampt/ PBEF/visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab. 2007;6(5):363-375.
77. Kover K, Tong PY, Watkins D, et al. Expression and regulation of Nampt in human islets. PLoS ONE. 2013;8(3):e58767.
78. Yamada K, Hara N, Shibata T, Osago H, Tsuchiya M. The simultaneous measurement of nicotinamide adenine dinucleotide and related compounds by liquid chromatography/ electrospray ionization tandem mass spectrometry. Anal Biochem. 2006;352(2): 282-285.